PP&E (Net)
Labcorp Holdings PP&E (Net) decreased by 0.5% to $3.07B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 0.8%, from $3.09B to $3.07B. Over 5 years (FY 2020 to FY 2025), PP&E (Net) shows an upward trend with a 2.5% CAGR.
Analysis
How to read this metric
An increase indicates ongoing investment in physical capacity, whereas a decline may suggest aging assets or a strategy of asset-light operations.
Detailed definition
This metric represents the book value of tangible assets after subtracting accumulated depreciation from the total histo...
Peer comparison
Standard line item for all manufacturing and industrial companies; directly comparable across peers.
property_plant_equipment_netHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.70B | $2.69B | $2.82B | $2.81B | $2.87B | $2.88B | $2.79B | $2.94B | $2.76B | $2.82B | $2.91B | $2.90B | $2.93B | $3.05B | $3.05B | $3.09B | $3.13B | $3.11B | $3.08B | $3.07B |
| QoQ Change | — | -0.4% | +4.6% | -0.3% | +2.2% | +0.5% | -3.1% | +5.4% | -6.2% | +2.1% | +3.2% | -0.5% | +1.2% | +4.0% | -0.2% | +1.5% | +1.4% | -0.7% | -1.0% | -0.5% |
| YoY Change | — | — | — | — | +6.2% | +7.2% | -0.8% | +4.9% | -3.8% | -2.2% | +4.2% | -1.6% | +6.2% | +8.1% | +4.6% | +6.7% | +6.9% | +2.1% | +1.2% | -0.8% |
Business Segments
| Segment | Q4 '21 | Q4 '22 | Q4 '23 |
|---|---|---|---|
| LabCorp Diagnostics | $1.51B | $1.67B | $1.80B |
| Covance Drug Development | $1.31B | $1.12B | — |
| Total | $2.82B | $2.79B | $2.91B |
Covance Drug Development, LabCorp Diagnostics were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Geographic Breakdown
| Segment | Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 |
|---|---|---|---|---|---|
| North America | $2.18B | $2.31B | $2.42B | $2.58B | $2.59B |
| Europe | $449.90M | $382.40M | $394.70M | $355.50M | $370.40M |
| Other countries | $188.00M | $102.70M | $98.90M | $113.80M | $124.00M |
| Total | $2.82B | $2.79B | $2.91B | $3.05B | $3.08B |
PP&E (Net) at Other Companies
Frequently Asked Questions
- What is Labcorp Holdings's pp&e (net)?
- Labcorp Holdings (LH) reported pp&e (net) of $3.07B in Q1 2026.
- How has Labcorp Holdings's pp&e (net) changed year-over-year?
- Labcorp Holdings's pp&e (net) decreased by 0.8% year-over-year, from $3.09B to $3.07B.
- What is the long-term trend for Labcorp Holdings's pp&e (net)?
- Over 5 years (2020 to 2025), Labcorp Holdings's pp&e (net) has grown at a 2.5% compound annual growth rate (CAGR), from $2.73B to $3.08B.
- What does pp&e (net) mean?
- The current book value of physical assets after accounting for wear and tear.